Related Experiment Videos
Cavitary pulmonary infarct in immunocompromised hosts
T I Morgenthaler1, J H Ryu, J P Utz
1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Abstract:
Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15% of cases, and only about 5% of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immuno-compromised patients with lung disease.
Insights
Cavitary pulmonary infarction, a rare condition in immunocompromised patients, can occur from pulmonary embolism. Early consideration is vital for diagnosing and treating this dangerous, yet treatable, lung disease.
Area of Science:
- Pulmonology
- Radiology
- Infectious Diseases
Background:
- Immunocompromised patients frequently develop pulmonary disease.
- Cavitary lung disease in this population is uncommon, typically linked to fungal or mycobacterial infections.
- Pulmonary embolism (PE) presents a rare, non-infectious etiology for cavitary pulmonary processes.
Observation:
- Pulmonary embolism leads to infarction in less than 15% of cases.
- Approximately 5% of pulmonary infarcts develop cavitation.
- This study details two cases of cavitary infarcts in immunocompromised individuals.
Findings:
- Cavitary pulmonary infarction is an infrequently reported complication in immunocompromised patients.
- This condition, though rare, is a significant cause of lung disease in this demographic.
- Pulmonary infarcts with cavitation are a critical differential diagnosis consideration.
Implications:
- Recognizing cavitary pulmonary infarction is crucial for timely diagnosis and treatment in immunocompromised patients.
- This condition, while dangerous, is treatable, emphasizing the need for its inclusion in differential diagnoses.
- Further research into the mechanisms and optimal management of cavitary pulmonary infarction in immunocompromised hosts is warranted.